11 June, 2017
ENDP has been the subject of several other research reports.
Endo International plc (ENDP) now has P/E (Price to Earnings) ratio of 0 while the company's industry has 13.96 P/E and the sector P/E is 18.75. Guardian Life Ins Of America holds 0% in Endo International plc - Ordinary Shares (NASDAQ:ENDP) or 770 shares. Endo International plc - has an average rating of "Hold" and an average price target of $19.14. William Blair reiterated a "market perform" rating on shares of Endo International plc - in a research report on Saturday, March 11th. Canaccord Genuity initiated coverage on shares of Endo International plc - in a report on Tuesday, February 21st. Shares have dropped -13.11% over the trailing 6 months.
WARNING: This report was reported by Transcript Daily and is the sole property of of Transcript Daily. If you are reading this report on another site, it was stolen and republished in violation of global trademark and copyright legislation. The legal version of this news story can be read at https://www.themarketsdaily.com/2017/06/10/endo-international-plc-endp-given-average-recommendation-of-hold-by-analysts-updated.html. Endo International plc had 43 analyst reports since August 11, 2015 according to SRatingsIntel. Given that its average daily volume over the 30 days has been 0.36 million shares a day, this signifies a pretty significant change over the norm. This company shares are 15.24% off its target price of $15.88 and the current market capitalization stands at $3.22B. Endo International plc - has a 52-week low of $9.70 and a 52-week high of $24.93.
During the most recent trading day, the stock's price shifted up+42.06 percent from its 52-week-low while -44.73 percent lower from its 52-week high. One investment analyst has rated the stock with a sell recommendation, fourteen have assigned a hold recommendation and six have issued a buy recommendation on the company.
Short traders are feeling a little more bullish on Endo International plc if you look at the fall in short interest. The firm had revenue of $1.04 billion for the quarter, compared to analysts' expectations of $1.02 billion. During the same quarter in the prior year, the company posted $1.08 earnings per share. The business's revenue for the quarter was up 7.7% compared to the same quarter a year ago.
Other equities analysts have also recently issued reports about the stock. Similarly, the company's last 5 years high P/E ratio is 181.18 and low P/E is 40.5, whereas, the industry's and sector's high P/E for the past year is 39.86 and 45.26 respectively and low P/E ratio for the last 5 years is 22.63 for the industry and 23.72 for the Sector.
Endo International plc - (NASDAQ:ENDP) last posted its quarterly earnings data on Tuesday, May 9th. OppenheimerFunds Inc. now owns 2,873,153 shares of the company's stock worth $32,065,000 after buying an additional 1,857,678 shares in the last quarter. State Street Corp boosted its stake in Endo International plc - by 5.3% in the fourth quarter. Van ECK Associates Corp now owns 197,960 shares of the company's stock valued at $2,209,000 after buying an additional 113,743 shares during the period.
Endo International plc - (NASDAQ:ENDP) last issued its quarterly earnings results on Tuesday, May 9th.
A number of hedge funds have recently bought and sold shares of the company. Finally, Acrospire Investment Management LLC increased its position in Endo International plc - by 139.3% in the third quarter. 54,100 are owned by Phoenix Invest Adviser Limited Liability Company. UBS reinitiated the shares of RF in report on Wednesday, January 11 with "Sell" rating. The stock was sold at an average price of $10.82, for a total value of $57,616.50. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Teachers Retirement System of The State of Kentucky now owns 36,400 shares of the company's stock valued at $406,000 after buying an additional 8,400 shares during the period. Its International Pharmaceuticals segment offers specialty pharmaceutical products in various therapeutic areas, including attention deficit hyperactivity disorder, pain, womens health, and oncology; generic, branded generic, and over-the-counter products in the areas of dermatology and anti-infectives; and healthcare services, products, and solutions to hospitals, pharmacies, and practitioners, as well as for government healthcare programs.
